These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23024987)

  • 1. NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
    Dyer M; Rinaldi F; George E; Adler AI
    Lancet Oncol; 2012 Aug; 13(8):762-3. PubMed ID: 23024987
    [No Abstract]   [Full Text] [Related]  

  • 2. [New treatments for castration-resistant prostate cancer].
    Sautois B; Gennigens C
    Rev Med Liege; 2013 Feb; 68(2):94-6. PubMed ID: 23469490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abiraterone and its place in the treatment of metastatic CRPC.
    Sartor O; Pal SK
    Nat Rev Clin Oncol; 2013 Jan; 10(1):6-8. PubMed ID: 23149889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
    Jilani A; George E; Adler AI
    Lancet Oncol; 2012 Jun; 13(6):573-4. PubMed ID: 22833888
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
    Ansari J; Hussain SA; Alhasso A; Mahmood R; Ansari A; Glaholm J
    Anticancer Agents Med Chem; 2011 Mar; 11(3):296-306. PubMed ID: 21426298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
    Aguiar PN; Tan PS; Simko S; Barreto CMN; Gutierres BS; Giglio AD; Lopes GL
    Einstein (Sao Paulo); 2019 Mar; 17(2):eGS4414. PubMed ID: 30843996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
    Sartor O; Michels RM; Massard C; de Bono JS
    Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
    Heck MM; Höppner M; Horn T; Thalgott M; Gschwend JE; Retz M
    Urologe A; 2012 Mar; 51(3):390-7. PubMed ID: 22331349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
    Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
    Ouzaid I; Ravery V; Pouessel D; Culine S
    Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Second line therapy for castration-resistant prostate cancer (CRPC)].
    Molitor B; Börgermann C
    Urologe A; 2012 Mar; 51(3):357-62. PubMed ID: 22113549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
    Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current clinical trials in castrate-resistant prostate cancer.
    Petrylak DP
    Curr Urol Rep; 2011 Jun; 12(3):173-9. PubMed ID: 21533748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New agents for the management of castration-resistant prostate cancer.
    Cersosimo RJ
    Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case on hemodialysis with castration-resistant prostate cancer which responded to combination chemotherapy with docetaxel and prednisolone].
    Ito H; Inamura S; Taga M; Tsuchiyama K; Kusukawa N; Oyama N; Akino H; Yokoyama O
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1245-7. PubMed ID: 24047790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.